UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines, 2021-06, Vol.9 (7), p.740

2021

Volltextzugriff (PDF)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Cancers, 2019-05, Vol.11 (6), p.737

2019

Volltextzugriff (PDF)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Gynecologic oncology, 2020-10, Vol.159 (1), p.150-156

2020

Volltextzugriff (PDF)

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer

Cancer discovery, 2020-02, Vol.10 (2), p.198-213

2020

Volltextzugriff (PDF)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Clinical cancer research, 2021-11, Vol.27 (21), p.5818-5827

2021

Volltextzugriff (PDF)

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

Gynecologic oncology, 2024-02, Vol.181, p.162-169

2024

Volltextzugriff (PDF)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer

Cancer drug resistance, 2022-01, Vol.5 (4), p.873-881

2022

Volltextzugriff (PDF)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Translational oncology, 2024-11, Vol.49, p.102073, Article 102073

2024

Volltextzugriff (PDF)

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE

Clinical cancer research, 2022-05, Vol.28 (10), p.2118-2130

2022

Volltextzugriff (PDF)

Abstract P2-13-39: Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-39

2022

Volltextzugriff (PDF)

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-28

2022

Volltextzugriff (PDF)

Abstract 2420: Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2420-2420

2021

Volltextzugriff (PDF)

Abstract PS4-07: Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-07-PS4-07

2021

Volltextzugriff (PDF)

Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1914-1914

2020

Volltextzugriff (PDF)

Abstract PS10-06: Comparative analysis of anti-proliferative effects and gene profiling of lapatinib, neratinib, and tucatinib

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS10-06-PS10-06

2021

Volltextzugriff (PDF)

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.310-310

2021

Volltextzugriff (PDF)

Abstract 4041: The EML4-ALK fusion protein mediates reduced sensitivity to the combination of neratinib and dasatinib

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4041-4041

2023

Volltextzugriff (PDF)

Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P6-P6-12-09

2023

Volltextzugriff (PDF)

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2 -mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS4-10-GS4-10

2022

Volltextzugriff (PDF)

Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-01-01

2022

Volltextzugriff (PDF)

Abstract 3988: Identification of HER4 mutations with potential as biomarkers of response to neratinib

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3988-3988

2022

Volltextzugriff (PDF)

Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket' trial

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5533-5533

2018

Volltextzugriff (PDF)

Abstract 3962: Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3962-3962

2023

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Aktive Filter

KollektionSingle Title from Nature Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(126)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(86)
Humans
(75)
Male
(45)
Female
(42)
Biological And Medical Sciences
(26)
Medical Sciences
(24)
Middle Aged
(19)
Adult
(18)
Oncology
(18)
Infectious Diseases
(16)
Aged
(14)
Animals
(13)
General & Internal Medicine
(12)
Medicine, General & Internal
(12)
Pharmacology. Drug Treatments
(12)
Infant, Newborn
(10)
Medicin Och Hälsovetenskap
(10)
Pediatrics
(10)
Public, Environmental & Occupational Health
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma

Abstract P2-13-39: Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Abstract 2420: Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib

Abstract PS4-07: Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference

Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer

Abstract PS10-06: Comparative analysis of anti-proliferative effects and gene profiling of lapatinib, neratinib, and tucatinib

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)

Abstract 4041: The EML4-ALK fusion protein mediates reduced sensitivity to the combination of neratinib and dasatinib

Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2 -mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models

Abstract 3988: Identification of HER4 mutations with potential as biomarkers of response to neratinib

Abstract 5533: Cell-free DNA sequencing in ERBB2-mutant breast cancer patients treated with neratinib and fulvestrant: Exploratory analysis from the Phase 2 SUMMIT ‘basket' trial

Abstract 3962: Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines

Aktive Filter

Suchergebnisse filtern